Exelixis, Inc. - Common Stock (EXEL)
42.51
+0.14 (0.33%)
NASDAQ · Last Trade: Jun 6th, 1:43 PM EDT

EXELIXIS INC (NASDAQ:EXEL) combines strong earnings momentum with a high technical rating, making it a standout for growth investors. The stock's breakout setup suggests potential upside.
Via Chartmill · June 6, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities.
Via Chartmill · June 3, 2025
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.
Via Chartmill · May 26, 2025
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
Via Chartmill · May 22, 2025
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.
Via Chartmill · May 20, 2025
Large-cap stocks surged in the last week. CoreWeave, Super Micro, Coinbase, NRG Energy, Astera Labs, First Solar, Exelixis, Rocket Lab, Hims & Hers, On Holding and Gap were the top performers.
Via Benzinga · May 18, 2025
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.
Via Chartmill · May 17, 2025
Exelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine tumor market.
Via Benzinga · May 14, 2025
Nasdaq 100 rises further as Nvidia and AMD rally on Middle East investment hopes, while gold tumbles and Treasury yields surge.
Via Benzinga · May 14, 2025
Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628.
Via Benzinga · May 14, 2025
The top-notch biotech company easily beat first-quarter profit expectations.
Via Investor's Business Daily · May 13, 2025
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate
Via Chartmill · May 1, 2025
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · April 28, 2025
A fundamental and technical analysis of (NASDAQ:EXEL): Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.
Via Chartmill · April 25, 2025
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL).
Via Chartmill · April 16, 2025